Mattinglywinther6890

001). Gender, age, education level, smoking, and treatment-related toxicity scores (P < 0.05) were independent risk factors for anxiety in patients with NPC during radiotherapy, while age, education level, and treatment-related toxicity scores (P < 0.05) were independent risk factors for depression in these patients.

The incidence and degree of anxiety and depression in NPC patients increased during radiotherapy. Age, education level, and treatment-related side effects influenced anxiety and depression. More psychological nursing should be given to the NPC patients who are more likely to suffer from psychological distress.

The incidence and degree of anxiety and depression in NPC patients increased during radiotherapy. Age, education level, and treatment-related side effects influenced anxiety and depression. More psychological nursing should be given to the NPC patients who are more likely to suffer from psychological distress.Anti-CD20 monoclonal antibody (mAb) therapy is a mainstay of therapy for B cell malignancies, however many patients fail to respond or eventually develop resistance. The current understanding of mechanisms responsible for this resistance is limited. When peripheral blood mononuclear cells of healthy donors were cultured with Raji cells for 7 days, rituximab (RTX) induced NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC), enhanced NK cell viability and increased or maintained NK expression of CD56, CD16, CD57 and KIR. T cells, mainly CD4+, mediated these changes in a contact-dependent manner, with local T cell production of IL2 playing a central role. Similar findings were found when autologous B cells were used as target cells demonstrating the need for T cell help was not due to allogenic reaction. Results with other anti-CD20 and anti-EGFR antibodies were consistent. Small numbers of T cells activated by anti-CD3/CD28 beads or bispecific antibody enhanced RTX-mediated NK cell ADCC, viability and phenotypical changes. Pathway analysis of bulk NK cell mRNA sequencing after activation by RTX with and without T cells was consistent with T cells maintaining the viability of the activated NK cells. These findings suggest T cell help, mediated in large part by local production of IL2, contributes to NK cell ADCC and viability, and that activating T cells in the tumor microenvironment, such as through the use of anti-CD3 based bispecific antibodies, could enhance the efficacy of anti-CD20 and other mAb therapies where NK-mediated ADCC is a primary mechanism of action.

There is an ongoing controversial debate about the effectiveness of laser treatments in chronic central serous chorioretinopathy (cCSC). We performed a prospective non-randomized interventional study to learn about the effects of a subthreshold laser treatment (Topcon Endpoint Management™, Topcon Healthcare Inc., Tokyo, Japan) in patients with cCSC.

Patients with cCSC and a minimum symptom duration of 4months were included and treated with a standardized laser pattern covering the macular area. Retreatment was performed every 3months if persistent subretinal fluid was observed. The primary endpoint was resolution of subretinal fluid at 6months. Further outcome parameters included best corrected visual acuity, microperimetry, central macular and subfoveal choroidal thickness.

A total of 42 eyes of 39 patients were included. Mean patient age was 48 ± 10.6years (range 25-67). Mean symptomatic time before inclusion into the study was 134 ± 133.4weeks (16-518). Before inclusion, 78.6% of the patients had failed to resolve subretinal fluid under mineralocorticoid receptor antagonists and 14.3% had a recurrence after half-dose photodynamic therapy. Complete resolution of subretinal fluid was observed in 42.9% at 6months and in 53.8% at 12months after baseline. Simvastatin Central retinal thickness decreased from 398 ± 135µm to 291 ± 68µm (p < 0.001), subfoveal choroidal thickness changed slightly (430 ± 116µm to 419 ± 113µm, p = 0.026), microperimetry-derived macular function improved by 19.1 ± 4.7dB to 21.3 ± 4.8dB (p = 0.008) and mean BCVA improved by 4.9 ± 8.6 ETDRS letters (p < 0.001).

The results show that the investigated laser treatment is effective in reducing subretinal fluid and leads to an improvement of functional parameters.

The results show that the investigated laser treatment is effective in reducing subretinal fluid and leads to an improvement of functional parameters.

To assess the degree of posterior capsular opacification (PCO) and its influence on contrast sensitivity defocus curve (CSDC) after implantation of two trifocal intraocular lenses (IOLs), Alsafit (AT) and Liberty (L), during a 12-month follow-up. A secondary aim was to evaluate the NdYAG capsulotomy rate in a long time.

Data from 63 subjects, 34 implanted with AT and 29 with L, were retrospectively analyzed for this pilot study. In those eyes without capsulotomy during the first year (n = 58), CSDC at 3 and 12months after surgery and PCO grading were measured, with additional answering of a visual function questionnaire (VF-14) and a question of general satisfaction. The period after surgery up to capsulotomy or last on-demand visit without NdYAG was recorded for survival analysis beyond the 12-month follow-up.

Total area under CSDC (TAUC) between 3 and 12months decreased from 2.96 to 1.71 for AT (p < 0.05) and from 2.73 to 2.21 (p > 0.05) for L. Of eyes, 51.6, 19.3, and 29% with AT were graded as level 0, 1, and 2 of PCO, while 85.1, 11.1, and 3.7% of eyes with L were graded as level 0, 1, and 2 (p < 0.05). PCO grading was correlated with a decrease of TAUC (ρ =  - 0.27, p = 0.04). Median time to require capsulotomy was 22months with AT and 30months with L (p < 0.05).

PCO decreases CSDC in patients with trifocal lenses. Despite using the same hydrophilic material, PCO grading and NdYAG capsulotomy rate was higher for AT than for L.

PCO decreases CSDC in patients with trifocal lenses. Despite using the same hydrophilic material, PCO grading and NdYAG capsulotomy rate was higher for AT than for L.

This meta-analysis was performed to evaluate the diagnostic value of optical coherence tomography angiography (OCTA) for active choroidal neovascularization (CNV) of all types and etiologies.

We searched the Web of Science, PubMed, Cochrane Library, Medline, and Embase databases for all interrelated published studies from inception to August 2020. Meta-disc and STATA were used for the data analyses. We measured the diagnostic value by assessing the pooled diagnostic sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the summary receiver operating characteristic curve (sROC AUC). Sources of heterogeneity were also analyzed.

Nine studies involving 785 eyes were included in the meta-analysis. The pooled sensitivity was 0.83 (95% confidence interval [CI], 0.75-0.88), specificity was 0.89 (95% CI, 0.79-0.94), PLR was 7.4 (95% CI, 3.8-14.6), NLR was 0.20 (95% CI, 0.13-0.29), and DOR was 38 (95% CI, 16-91). The sROC AUC was 0.91 (95% CI, 0.89-0.94). With respect to heterogeneity, the sensitivity of the fluorescein angiography (FA) reference standard group (0.71 [0.64-0.78]) and developed country group (0.77 [0.70-0.84]) was both lower than the sensitivity of the FA combined with optical coherence tomography (OCT) reference standard group (0.89 [0.84-0.93], P < 0.001) and developing country group (0.90 [0.85-0.95], P < 0.001).

This meta-analysis suggests that OCTA is a non-invasive, convenient diagnostic method for active CNV and has high diagnostic value. Moreover, the accuracy of the diagnostic accuracy is independent of the types of device, algorithms, and the etiology of CNV.

This meta-analysis suggests that OCTA is a non-invasive, convenient diagnostic method for active CNV and has high diagnostic value. Moreover, the accuracy of the diagnostic accuracy is independent of the types of device, algorithms, and the etiology of CNV.

In this study, we investigated the association between the early response of serum and hematological variables and the outcome of cabazitaxel therapy.

The medical records of 59 consecutive patients who had previously received docetaxel chemotherapy for the treatment of metastatic castration-resistant prostate cancer (CRPC) and who received cabazitaxel at our hospital between January 2011 and March 2020 were retrospectively reviewed and statistically analyzed.

The median follow-up period after cabazitaxel initiation was 15.2months. The 30% prostate-specific antigen (PSA) response rate, median PSA progression-free survival period, and overall survival (OS) period were 45.8%, 4.3months, and 22.6months, respectively. Within 1 to 2 cycles of cabazitaxel, we were unable to identify hematological or serum kinetics that had a relationship with OS. Analysis of the variables after 3 cycles of cabazitaxel, however, revealed two factors, PSA decline > 30% (p = 0.016) and neutrophil-lymphocyte ratio (NLR) decline > 30% (p = 0.044), as the predictors of favorable outcome for OS. We established a prognostic model for predicting the OS period composed of these two factors, which exhibited distinctly separated OS curves (p = 0.004). The C-index of a model incorporating these two factors was 0.703.

This is the first study to demonstrate that PSA and NLR decline 3 cycles after the initiation of cabazitaxel were associated with favorable outcome in patients with CRPC. Also, 3 cycles of cabazitaxel might be necessary to assess the efficacy of cabazitaxel therapy.

This is the first study to demonstrate that PSA and NLR decline 3 cycles after the initiation of cabazitaxel were associated with favorable outcome in patients with CRPC. Also, 3 cycles of cabazitaxel might be necessary to assess the efficacy of cabazitaxel therapy.Adamantinoma-like Ewing sarcoma is uncommonly reported in the skeletal sites, including small bones of the feet.A 15-year-old girl presented with pain and swelling in her left foot, leading to difficulty in walking for 8 months. Plain radiograph revealed an ill-defined, lytic-sclerotic lesion without significant periosteal reaction in her left calcaneus. Magnetic resonance imaging (MRI) revealed an expansile lesion involving the anterior calcaneus, which was hypointense on T1 and heterogeneously hyperintense on T2-weighted sequences, infiltrating the adjacent bones and soft tissues. On imaging, the differential diagnoses considered were a giant cell tumor and other primary bone tumors.Histopathological examination revealed a tumor composed of small round cells, with interspersed keratin pearls. Immunohistochemically, the tumor cells were positive for CD99/MIC2, pan-cytokeratin (AE1/AE3), p40, p63, NKX2.2, and synaptophysin. Diagnosis of adamantinoma-like Ewing sarcoma was offered on the initial biopsy. Furthermore, the tumor cells revealed EWSR1 gene rearrangement by fluorescence in situ hybridization, confirming this diagnosis. The patient underwent neoadjuvant chemotherapy, had a poor response, and finally underwent below-knee amputation.This constitutes a rare case of adamantinoma-like Ewing sarcoma in the calcaneus. Ewing sarcoma may be considered as a differential diagnosis for intraosseous lytic-sclerotic lesions, even without significant periosteal reaction, at unusual sites, such as the bones of the foot. Awareness of this entity and application of ancillary techniques is recommended for its exact diagnosis and in differentiating this rare variant from its diagnostic mimics. This case also indicates a poor chemotherapy response in this unusual variant of Ewing sarcoma, occurring in the calcaneus.